STROKE, MAKE PREVENTION
By appropriately closing PFOs associated with cryptogenic stroke with the AMPLATZER™ PFO Occluder, physicians can significantly reduce the risk of stroke recurrence.
THE TURNING POINT FOR CRYPTOGENIC STROKE TREATMENT
Three large clinical studies confirm the superiority of PFO closure to medical management in reducing risk of stroke recurrence.1-3
WHICH OF YOUR PATIENTS CAN BENEFIT FROM:
Reduced risk of recurrence? Excellent safety profile?
THE SOLUTION: PFO CLOSURE
- Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377: 1033-42.
- Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377: 1022-32.
- Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-21 and supplementary appendix.